The Swedish pharmaceutical company Oncopeptides AB has announced the appointment of Marty Duvall as chief executive. Mr Duvall has held a number of senior positions in pharma and biotech, most recently as CEO of the US gene therapy company Tocagen Inc. He assumes the top job at Oncopeptides from Jakob Lindberg who becomes chief scientific officer. Oncopeptides recently submitted a new drug application to the US Food and Drug Administration for the oncology drug melflufen.
Oncopeptides announced the appointment on 30 June 2020.
Copyright 2020 Evernow Publishing Ltd